 A message from Sideways Frequency |
|
BioStem Technologies (BSEM) Surges Ahead with Record Revenues, Insider Buying, and Breakthrough Clinical Pipeline—Could This Be the Next Big Winner in MedTech? BioStem Technologies Inc. (OTC: BSEM) is redefining the future of regenerative medicine and wound care — and the market is starting to take notice. The company develops groundbreaking therapies designed to accelerate healing in chronic and complex wounds, including diabetic foot ulcers and venous leg ulcers. Its flagship VendajeAC line and expanding portfolio of advanced regenerative products are winning rapid adoption across hospitals, clinics, and specialty care centers, fueling a massive surge in revenue. In Q2 2025, BioStem posted preliminary Q2 2025 results, generating $49.3 million in net revenue and achieving the sixth consecutive quarter of positive adjusted EBITDA at $2.5 million. Cash reserves increased to $30.8 million, up $4.1 million from the previous quarter. Key business developments include the appointment of Brandon Poe as CFO, completion of enrollment in a pivotal clinical trial for BioREtain® Amnion Chorion targeting diabetic foot ulcers (with data expected in Q4 2025), expansion of the commercial organization to access new sites of care, and growth of the intellectual property portfolio to 58 issued patents and 68 pending. The excitement doesn’t stop there. BSEM insiders are snapping up shares, signaling strong confidence in the company’s near-term upside, while its clinical pipeline accelerates with pivotal trials for diabetic foot ulcers and new studies for venous leg ulcers. And with a potential uplisting to a senior stock exchange under review, BSEM is on the brink of massive visibility and market recognition. This combination of record revenues, insider conviction, robust cash reserves, and cutting-edge therapies makes BioStem Technologies one of the rare high-growth MedTech opportunities out there.
|
| This message is a paid advertisement for Biostem Technologies from Sideways Frequency. Schaeffer’s Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer’s Investment Research Inc. and its principals are not affiliated with Biostem Technologies. Schaeffer’s Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer’s Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer’s Investment Research Inc. to buy or sell any security. Schaeffer’s Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer’s Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Biostem Technologies on Biostem Technologies website for additional information. |
0 Response to "BSEM: Record Revenue Makes This a High-Growth MedTech Opportunity!"
Post a Comment